According to Fosun Pharmaceutical's announcement, in the first three quarters of 2026, it achieved operating income of 30.463 billion yuan, an increase of 3.64%; net profit attributable to shareholders of listed companies was 3.879 billion yuan, an increase of 15.18%; after deducting non-net profit of 2,667 billion yuan, a year-on-year decrease of 8.32%. The third quarter of 2026 achieved operating income of 10.021 billion yuan, an increase of 1.44% year on year; net profit attributable to shareholders of listed companies was 1,292 billion yuan, an increase of 15.49% year on year; after deducting non-net profit of 946 million yuan. The total R&D investment in the first three quarters was 5.247 billion yuan, up 31.24% year on year. Revenue from innovative drugs increased 15.54% year on year, accounting for 35.43% of pharmaceutical business revenue. During the reporting period, 2 innovative drugs were approved for marketing, 1 innovative drug marketing application was accepted, and 5 innovative drug clinical trial applications were approved.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.